JP2019534884A5 - - Google Patents

Download PDF

Info

Publication number
JP2019534884A5
JP2019534884A5 JP2019519252A JP2019519252A JP2019534884A5 JP 2019534884 A5 JP2019534884 A5 JP 2019534884A5 JP 2019519252 A JP2019519252 A JP 2019519252A JP 2019519252 A JP2019519252 A JP 2019519252A JP 2019534884 A5 JP2019534884 A5 JP 2019534884A5
Authority
JP
Japan
Prior art keywords
antigenic peptide
nucleic acid
amino acid
immunogenic
immunogenic compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019519252A
Other languages
English (en)
Japanese (ja)
Other versions
JP7116278B2 (ja
JP2019534884A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2017/075673 external-priority patent/WO2018065623A2/en
Publication of JP2019534884A publication Critical patent/JP2019534884A/ja
Publication of JP2019534884A5 publication Critical patent/JP2019534884A5/ja
Priority to JP2022096260A priority Critical patent/JP7331207B2/ja
Application granted granted Critical
Publication of JP7116278B2 publication Critical patent/JP7116278B2/ja
Priority to JP2023129666A priority patent/JP7648311B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019519252A 2016-10-07 2017-10-09 癌治療のための免疫原性化合物 Active JP7116278B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022096260A JP7331207B2 (ja) 2016-10-07 2022-06-15 癌治療のための免疫原性化合物
JP2023129666A JP7648311B2 (ja) 2016-10-07 2023-08-09 癌治療のための免疫原性化合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16192948 2016-10-07
EP16192948.4 2016-10-07
PCT/EP2017/075673 WO2018065623A2 (en) 2016-10-07 2017-10-09 Immunogenic compounds for cancer therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022096260A Division JP7331207B2 (ja) 2016-10-07 2022-06-15 癌治療のための免疫原性化合物

Publications (3)

Publication Number Publication Date
JP2019534884A JP2019534884A (ja) 2019-12-05
JP2019534884A5 true JP2019534884A5 (OSRAM) 2020-11-19
JP7116278B2 JP7116278B2 (ja) 2022-08-10

Family

ID=57123864

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019519252A Active JP7116278B2 (ja) 2016-10-07 2017-10-09 癌治療のための免疫原性化合物
JP2022096260A Active JP7331207B2 (ja) 2016-10-07 2022-06-15 癌治療のための免疫原性化合物
JP2023129666A Active JP7648311B2 (ja) 2016-10-07 2023-08-09 癌治療のための免疫原性化合物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022096260A Active JP7331207B2 (ja) 2016-10-07 2022-06-15 癌治療のための免疫原性化合物
JP2023129666A Active JP7648311B2 (ja) 2016-10-07 2023-08-09 癌治療のための免疫原性化合物

Country Status (9)

Country Link
US (2) US11478537B2 (OSRAM)
EP (1) EP3522915A2 (OSRAM)
JP (3) JP7116278B2 (OSRAM)
KR (2) KR102686875B1 (OSRAM)
CN (2) CN117801066A (OSRAM)
AU (3) AU2017339577B2 (OSRAM)
CA (1) CA3039322A1 (OSRAM)
IL (3) IL302345B2 (OSRAM)
WO (1) WO2018065623A2 (OSRAM)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3522916A2 (en) 2016-10-07 2019-08-14 Enterome S.A. Immunogenic compounds for cancer therapy
IL302345B2 (en) 2016-10-07 2024-12-01 Enterome S A Immunogenic compounds for cancer therapy
WO2018065628A2 (en) 2016-10-07 2018-04-12 Enterome Microbiota sequence variants of tumor-related antigenic epitopes
HRP20230007T1 (hr) 2018-04-11 2023-03-03 Enterome S.A. Antigenski peptidi, namijenjeni sprječavanju i liječenju raka
EP4021487B1 (en) * 2019-11-15 2023-12-27 Enterome S.A. Antigenic peptides for prevention and treatment of b-cell malignancy
WO2022015766A1 (en) * 2020-07-13 2022-01-20 Oregon Health & Science University Immunogenic constructs, compositions, and methods for inducing immune response
CN112010960A (zh) * 2020-09-10 2020-12-01 热休(厦门)细胞生物科技有限公司 一种肿瘤抗原复合物体外致敏dc、t细胞获得肿瘤特异性杀伤细胞ctl及其制备方法
US20220383996A1 (en) * 2021-05-27 2022-12-01 Amazon Technologies, Inc. Assigning peptides to peptide groups for vaccine development

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3841091A1 (de) 1988-12-07 1990-06-13 Behringwerke Ag Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
EP0378881B1 (en) 1989-01-17 1993-06-09 ENIRICERCHE S.p.A. Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
US7252829B1 (en) * 1998-06-17 2007-08-07 Idm Pharma, Inc. HLA binding peptides and their uses
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
US5550214A (en) * 1994-02-10 1996-08-27 Brigham And Women's Hospital Isolated antigenic oncogene peptide fragments and uses
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
EP1162999B1 (en) 1999-03-19 2006-11-29 Glaxosmithkline Biologicals S.A. Vaccine against Streptococcus pneumoniae
JP2002541808A (ja) 1999-04-09 2002-12-10 テクラブ, インコーポレイテッド ポリサッカリド結合体ワクチンのための組換えトキシンaタンパク質キャリア
CA2370413A1 (en) 1999-06-29 2001-01-04 Epimmune Inc. Hla binding peptides and their uses
EP1239866A4 (en) * 1999-12-10 2005-02-09 Epimmune Inc INDUCTION OF HER2 / NEU CELLULAR IMMUNE RESPONSES USING PEPTIDE AND NUCLEIC ACID-CONTAINING COMPOSITIONS
JP2004511425A (ja) 2000-02-08 2004-04-15 ザ ペン ステート リサーチ ファウンデーション 免疫療法に使用されるインターロイキン13受容体サブユニットアルファー2
WO2001062776A1 (en) 2000-02-23 2001-08-30 Epimmune Inc. Hla binding peptides and their uses
US7892559B2 (en) 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
CA2480008C (en) 2002-03-22 2015-10-06 The Penn State Research Foundation Use of il-13 receptor subunit alpha 2 as an anti-cancer vaccine
EP1578432A4 (en) 2002-10-03 2008-07-30 Epimmune Inc HLA BINDING PEPTIDES AND USES THEREOF
WO2005076001A2 (en) * 2004-02-06 2005-08-18 Inserm (Institut National De La Sante Et De La Recherche Medicale) A polypeptide derived from gp41, a vaccine composition comprising said polypeptide, and uses for treating an infection by an hiv virus in an individual
WO2006034334A2 (en) 2004-09-21 2006-03-30 University Of Pittsburgh Of The Commonwealth System Of Higher Education Peptide analogs capable of enhancing stimulation of a glioma-specific ctl response
US7666622B2 (en) 2005-10-19 2010-02-23 Regeneron Pharmaceuticals, Inc. Monomeric self-associating fusion polypeptides and therapeutic uses thereof
BRPI0720280A2 (pt) 2006-12-11 2014-01-28 Wyeth Corp Métodos e composições para tratar e monitorar tratamento de desordens associadas à il-13
JP2010190572A (ja) * 2007-06-01 2010-09-02 Sapporo Medical Univ IL13Ra2に対する抗体およびこれを含む診断・治療薬
NZ600758A (en) 2007-06-18 2013-09-27 Merck Sharp & Dohme Antibodies to human programmed death receptor pd-1
CN108117584B (zh) 2007-08-20 2021-08-24 肿瘤疗法科学股份有限公司 Foxm1肽和包含foxm1肽的药剂
US20110182926A1 (en) * 2008-08-12 2011-07-28 Nicola La Monica Minigene
WO2010077634A1 (en) 2008-12-09 2010-07-08 Genentech, Inc. Anti-pd-l1 antibodies and their use to enhance t-cell function
US20110033389A1 (en) * 2009-04-29 2011-02-10 Zhifeng Chen Modified antibodies for passive immunotherapy
NZ599405A (en) 2009-11-24 2014-09-26 Medimmune Ltd Targeted binding agents against b7-h1
WO2011140284A2 (en) 2010-05-04 2011-11-10 Fred Hutchinson Cancer Research Center Conditional superagonist ctl ligands for the promotion of tumor-specific ctl responses
EP4159226A1 (en) 2010-08-24 2023-04-05 University of Pittsburgh - Of the Commonwealth System of Higher Education Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines
EP2639299A1 (en) 2012-03-16 2013-09-18 Invectys Universal cancer peptides derived from telomerase
EP4361634A3 (en) 2012-03-19 2024-06-05 Stemline Therapeutics, Inc. Methods for treating and monitoring the status of cancer
WO2013148147A1 (en) 2012-03-26 2013-10-03 The U.S.A., As Represented By The Secretary Dept. Of Health And Human Services Dna methylation analysis for the diagnosis, prognosis and treatment of adrenal neoplasms
HUE056350T2 (hu) 2012-05-16 2022-02-28 Stemline Therapeutics Inc Rákos õssejt célzott rák elleni vakcinák
US20140141044A1 (en) * 2012-11-12 2014-05-22 Dana-Farber Cancer Institute, Inc. Cord Colitis Syndrome Pathogen
CA3138788A1 (en) 2012-12-05 2014-06-12 Sola Biosciences Llc Protein expression enhancing polypeptides
US9764037B2 (en) 2012-12-06 2017-09-19 Victoria Link Limited Conjugate compounds
KR20160016725A (ko) * 2014-08-05 2016-02-15 주식회사 유영제약 암 세포에 과발현되는 IL13Rα2에 특이적으로 결합하는 키메라 항원 수용체로 변형된 T 세포
CA2976656A1 (en) 2015-02-16 2016-08-25 The Trustees Of The University Of Pennsylvania A fully-human t-cell receptor specific for the 369-377 epitope derived from the her2/neu (erbb2) receptor protein
US20180133327A1 (en) 2015-03-16 2018-05-17 Amal Therapeutics Sa Cell Penetrating Peptides and Complexes Comprising the Same
CN108026513A (zh) * 2015-03-31 2018-05-11 新加坡科技研究局 树突状细胞的抗原加载的方法和疫苗
EP3464630A1 (en) 2016-05-23 2019-04-10 Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. Methods of diagnosing cancer using cancer testis antigens
EP3522916A2 (en) 2016-10-07 2019-08-14 Enterome S.A. Immunogenic compounds for cancer therapy
WO2018065628A2 (en) 2016-10-07 2018-04-12 Enterome Microbiota sequence variants of tumor-related antigenic epitopes
IL302345B2 (en) 2016-10-07 2024-12-01 Enterome S A Immunogenic compounds for cancer therapy
EP3694541A2 (en) 2017-10-09 2020-08-19 Enterome S.A. Microbiota sequence variants of tumor-related antigenic epitopes
HRP20230007T1 (hr) 2018-04-11 2023-03-03 Enterome S.A. Antigenski peptidi, namijenjeni sprječavanju i liječenju raka
WO2019197563A2 (en) 2018-04-11 2019-10-17 Enterome S.A. Immunogenic compounds for treatment of fibrosis, autoimmune diseases and inflammation
US20230105457A1 (en) 2019-10-16 2023-04-06 Enterome S.A. Immunogenic Compounds For Treatment Of Adrenal Cancer
EP4021487B1 (en) 2019-11-15 2023-12-27 Enterome S.A. Antigenic peptides for prevention and treatment of b-cell malignancy

Similar Documents

Publication Publication Date Title
JP2019534884A5 (OSRAM)
JP2008538183A5 (OSRAM)
JP2015096070A5 (OSRAM)
JP2010506826A5 (OSRAM)
JP2013507907A5 (OSRAM)
JP2017006120A5 (OSRAM)
JP2008525033A5 (OSRAM)
JP2014500724A5 (OSRAM)
JP2017532966A5 (OSRAM)
JP2008529558A5 (OSRAM)
JP2010166916A5 (OSRAM)
JP2018518457A5 (OSRAM)
JP2015514132A5 (OSRAM)
JP2010227101A5 (OSRAM)
JP2017524380A5 (ja) 腫瘍血管遮断剤であるポリペプチド、遺伝子、発現ベクター、腫瘍血管遮断剤の組成物、及び腫瘍血管遮断剤であるポリペプチドの調製方法
RU2016146198A (ru) Терапевтические dll4-связывающие белки
JP2017537622A5 (OSRAM)
JP2015520178A5 (OSRAM)
JP2012115277A5 (OSRAM)
JP2012529293A5 (OSRAM)
JP2013172743A5 (OSRAM)
JP2015522264A5 (OSRAM)
JP2012515557A5 (OSRAM)
JP2011523857A5 (OSRAM)
JP2012505657A5 (OSRAM)